A recent study has further reported that the histone deacetylase 6 (HDAC6) plays an oncogenic role in DLBCL via indirect activation of c-MET signaling: the efficacy of a combined therapy with Ricolinostat (HDAC6 inhibitor: 1–2.5 μM) and Crizotinib (13–75 μM) was here demonstrated. This evidence concerns the gene HDAC6 and diffuse large B-cell lymphoma.